{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:16Z","timestamp":1794047356361,"version":"4.8.0"},"reference-count":43,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are incurable hematological malignancies that are pathologically linked with aberrant NF-\u03baB activation. In this study, we identified a group of novel C8-linked benzofused Pyrrolo[2,1-c][1,4]benzodiazepines (PBD) monomeric hybrids capable of sequence-selective inhibition of NF-\u03baB with low nanomolar LD50 values in CLL (n=46) and MM cell lines (n=5). The lead compound, DC-1-192, significantly inhibited NF-\u03baB DNA binding after just 4h exposure and demonstrating inhibitory effects on both canonical and non-canonical NF-\u03baB subunits. In primary CLL cells, sensitivity to DC-1-192 was inversely correlated with RelA subunit expression (r2=0.2) and samples with BIRC3 or NOTCH1 mutations showed increased sensitivity (P=0.001). RNA-sequencing and gene set enrichment analysis confirmed the over-representation of NF-\u03baB regulated genes in the down-regulated gene list. Furthermore, In vivo efficacy studies in NOD\/SCID mice, using a systemic RPMI 8226 human multiple myeloma xenograft model, showed that DC-1-192 significantly prolonged survival (P=0.017). In addition, DC1-192 showed synergy with bortezomib and ibrutinib; synergy with ibrutinib was enhanced when CLL cells were co-cultured on CD40L-expressing fibroblasts in order to mimic the cytoprotective lymph node microenvironment (P = 0.01). Given that NF-\u03baB plays a role in both bortezomib and ibrutinib resistance mechanisms, these data provide a strong rationale for the use of DC-1-192 in the treatment of NF-\u03baB-driven cancers, particularly in the context of relapsed\/refractory disease.<\/jats:p>","DOI":"10.3324\/haematol.2019.238584","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T14:06:11Z","timestamp":1588860371000},"page":"958-967","source":"Crossref","is-referenced-by-count":8,"title":["Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-\u03baB activity and synergise with bortezomib and ibrutinib in hematological cancers"],"prefix":"10.3324","volume":"106","author":[{"family":"Thomas Lewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"David B. Corcoran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"David E. Thurston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Peter J. Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Kevin Ashelford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Elisabeth J. Walsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Christopher D. Fegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Andrea G.S. Pepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Khondaker Miraz Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Chris Pepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,5,7]]},"reference":[{"key":"24602","doi-asserted-by":"crossref","unstructured":"Zheng C, Yin Q, Wu H. Structural studies of NF-\u03baB signaling. Cell Res. 2011; 21(1):183-195.","DOI":"10.1038\/cr.2010.171"},{"key":"24603","doi-asserted-by":"crossref","unstructured":"Gasparini C, Celeghini C, Monasta L, Zauli G. NF-\u03baB pathways in hematological malignancies. Cell Mol Life Sci. 2014; 71(11):2083-2102.","DOI":"10.1007\/s00018-013-1545-4"},{"key":"24604","doi-asserted-by":"crossref","unstructured":"Hoffmann A, Natoli G, Ghosh G. Transcriptional regulation via the NFkappaB signaling module. Oncogene. 2006; 25(51):6706-6716.","DOI":"10.1038\/sj.onc.1209933"},{"key":"24605","doi-asserted-by":"crossref","unstructured":"Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P, Kroemer G. Targeting NF-kappaB in hematologic malignancies. Cell Death Differ. 2006; 13(5):748-758.","DOI":"10.1038\/sj.cdd.4401874"},{"key":"24606","doi-asserted-by":"crossref","unstructured":"Abdi J, Chen G, Chang H. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget. 2013; 4(12):2186-2207.","DOI":"10.18632\/oncotarget.1497"},{"key":"24607","doi-asserted-by":"crossref","unstructured":"Hewamana S, Alghazal S, Lin TT. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood. 2008; 111(9):4681-4689.","DOI":"10.1182\/blood-2007-11-125278"},{"key":"24608","doi-asserted-by":"crossref","unstructured":"Merchionne F, Perosa F, Dammacco F. New therapies in multiple myeloma. Clin Exp Med. 2007; 7(3):83-97.","DOI":"10.1007\/s10238-007-0134-y"},{"key":"24609","doi-asserted-by":"crossref","unstructured":"Byrd JC, Brown JR, O\u2019Brien S. RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371(3):213-223.","DOI":"10.1056\/NEJMoa1400376"},{"key":"24610","doi-asserted-by":"crossref","unstructured":"Hideshima T, Ikeda H, Chauhan D. Bortezomib induces canonical nuclear factor- kappaB activation in multiple myeloma cells. Blood. 2009; 114(5):1046-1052.","DOI":"10.1182\/blood-2009-01-199604"},{"key":"24611","doi-asserted-by":"crossref","unstructured":"Ahn IE, Underbayev C, Albitar A. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood. 2017; 129(11):1469-1479.","DOI":"10.1182\/blood-2016-06-719294"},{"key":"24612","doi-asserted-by":"crossref","unstructured":"Wang CY, Mayo MW, Baldwin AS. TNFand cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science. 1996; 274(5288):784-787.","DOI":"10.1126\/science.274.5288.784"},{"key":"24613","doi-asserted-by":"crossref","unstructured":"Hideshima T, Chauhan D, Richardson P. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002; 277(19):16639-16647.","DOI":"10.1074\/jbc.M200360200"},{"key":"24614","doi-asserted-by":"crossref","unstructured":"Pepper C, Hewamana S, Brennan P, Fegan C. NF-kappaB as a prognostic marker and therapeutic target in chronic lymphocytic leukemia. Future Oncol. 2009; 5(7):1027-1037.","DOI":"10.2217\/fon.09.72"},{"key":"24615","doi-asserted-by":"crossref","unstructured":"Antonow D, Thurston DE. Synthesis of DNA-interactive pyrrolo[2,1-c [1,4]benzodiazepines (PBDs). Chem Rev. 2011; 111(4):2815-2864.","DOI":"10.1021\/cr100120f"},{"key":"24616","doi-asserted-by":"crossref","unstructured":"Gerratana B. Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines. Med Res Rev. 2012; 32(2):254-293.","DOI":"10.1002\/med.20212"},{"key":"24617","doi-asserted-by":"crossref","unstructured":"Rahman KM, Vassoler H, James CH, Thurston DE. DNA sequence preference and adduct orientation of pyrrolo[2,1- c][1,4]benzodiazepine antitumor agents. ACS Med Chem Lett. 2010; 1(8):427-432.","DOI":"10.1021\/ml100131b"},{"key":"24618","doi-asserted-by":"crossref","unstructured":"Puzanov I, Lee W, Chen AP. Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. Clin Cancer Res. 2011; 17(11):3794-3802.","DOI":"10.1158\/1078-0432.CCR-10-2056"},{"key":"24619","doi-asserted-by":"crossref","unstructured":"Mantaj J, Jackson PJ, Rahman KM, Thurston DE. From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody-drug conjugates (ADCs). Angew Chem Int Ed Engl. 2017; 56(2):462-488.","DOI":"10.1002\/anie.201510610"},{"key":"24620","doi-asserted-by":"crossref","unstructured":"Kotecha M, Kluza J, Wells G. Inhibition of DNA binding of the NF-Y transcription factor by the pyrrolobenzodiazepinepolyamide conjugate GWL-78. Mol Cancer Ther. 2008; 7(5):1319-1328.","DOI":"10.1158\/1535-7163.MCT-07-0475"},{"key":"24621","doi-asserted-by":"crossref","unstructured":"Hu WP, Tsai FY, Yu HS, Sung PJ, Chang LS, Wang JJ. Induction of apoptosis by DC-81- indole conjugate agent through NF-kappaB and JNK\/AP-1 pathway. Chem Res Toxicol. 2008; 21(7):1330-1336.","DOI":"10.1021\/tx700394h"},{"key":"24622","doi-asserted-by":"crossref","unstructured":"Rahman KM, Jackson PJ, James CH. GC-targeted C8-linked pyrrolobenzodiazepine- biaryl conjugates with femtomolar in vitro cytotoxicity and in vivo antitumor activity in mouse models. J Med Chem. 2013; 56(7):2911-2935.","DOI":"10.1021\/jm301882a"},{"key":"24623","doi-asserted-by":"crossref","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou- Talalay method. Cancer Res. 2010; 70(2):440-446.","DOI":"10.1158\/0008-5472.CAN-09-1947"},{"key":"24624","doi-asserted-by":"crossref","unstructured":"Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM. Classical and\/or alternative NF-kappaB pathway activation in multiple myeloma. Blood. 2010; 115(17):3541-3552.","DOI":"10.1182\/blood-2009-09-243535"},{"key":"24625","doi-asserted-by":"crossref","unstructured":"Keats JJ, Fonseca R, Chesi M. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007; 12(2):131-144.","DOI":"10.1016\/j.ccr.2007.07.003"},{"key":"24626","doi-asserted-by":"crossref","unstructured":"Zhang B, Kirov S, Snoddy J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res. 2005; 33(Web Server issue):W741-48.","DOI":"10.1093\/nar\/gki475"},{"key":"24627","doi-asserted-by":"crossref","unstructured":"Hertlein E, Byrd JC. Signalling to drug resistance in CLL. Best Pract Res Clin Haematol. 2010; 23(1):121-131.","DOI":"10.1016\/j.beha.2010.01.007"},{"key":"24628","doi-asserted-by":"crossref","unstructured":"Markovina S, Callander NS, O'Connor SL. Bortezomib-resistant nuclear factorkappaB activity in multiple myeloma cells. Mol Cancer Res. 2008; 6(8):1356-1364.","DOI":"10.1158\/1541-7786.MCR-08-0108"},{"key":"24629","doi-asserted-by":"crossref","unstructured":"Diop F, Moia R, Favini C. Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia. Haematologica. 2020; 105(2):448-456.","DOI":"10.3324\/haematol.2019.219550"},{"key":"24630","doi-asserted-by":"crossref","unstructured":"Benedetti D, Tissino E, Pozzo F. NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-\u03baB pathways. Leukemia. 2018; 32(3):654-662.","DOI":"10.1038\/leu.2017.296"},{"key":"24631","doi-asserted-by":"crossref","unstructured":"Asslaber D, Wacht N, Leisch M, Qi Y. BIRC3 expression predicts CLL progression and defines treatment sensitivity via enhanced NF-\u03baB nuclear translocation. Clin Cancer Res. 2019; 25(6):1901-1912.","DOI":"10.1158\/1078-0432.CCR-18-1548"},{"key":"24632","doi-asserted-by":"crossref","unstructured":"Del Poeta G, Dal Bo M, Del Principe MI. Clinical significance of c.7544-7545 del CT NOTCH1 mutation in chronic lymphocytic leukaemia. Br J Haematol. 2013; 160(3):415-418.","DOI":"10.1111\/bjh.12128"},{"key":"24633","doi-asserted-by":"crossref","unstructured":"Rossi D, Rasi S, Fabbri G. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood. 2012; 119(2):521.","DOI":"10.1182\/blood-2011-09-379966"},{"key":"24634","doi-asserted-by":"crossref","unstructured":"Hoffmann A, Levchenko A, Scott ML, Baltimore D. The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science. 2002; 298(5596):1241-1245.","DOI":"10.1126\/science.1071914"},{"key":"24635","doi-asserted-by":"crossref","unstructured":"Natoli G, Chiocca S. Nuclear ubiquitin ligases, NF-kappaB degradation, and the control of inflammation. Sci Signal. 2008; 1(1):pe1.","DOI":"10.1126\/stke.11pe1"},{"key":"24636","doi-asserted-by":"crossref","unstructured":"Godwin P, Baird AM, Heavey S, Barr MP, O'Byrne KJ, Gately K. Targeting nuclear factor- kappa B to overcome resistance to chemotherapy. Front Oncol. 2013; 3:120.","DOI":"10.3389\/fonc.2013.00120"},{"key":"24637","doi-asserted-by":"crossref","unstructured":"Baumann P, Mandl-Weber S, Oduncu F, Schmidmaier R. Alkylating agents induce activation of NFkappaB in multiple myeloma cells. Leuk Res. 2008; 32(7):1144-1147.","DOI":"10.1016\/j.leukres.2007.11.015"},{"key":"24638","doi-asserted-by":"crossref","unstructured":"San Miguel JF, Schlag R, Khuageva NK. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008; 359(9):906-917.","DOI":"10.1056\/NEJMoa0801479"},{"key":"24639","doi-asserted-by":"crossref","unstructured":"Murray MY, Auger MJ, Bowles KM. Overcoming bortezomib resistance in 548 multiple myeloma. Biochem Soc Trans. 2014; 42(4):804-808.","DOI":"10.1042\/BST20140126"},{"key":"24640","doi-asserted-by":"crossref","unstructured":"Woyach JA, Bojnik E, Ruppert AS. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood. 2014; 123(8):1207-1213.","DOI":"10.1182\/blood-2013-07-515361"},{"key":"24641","doi-asserted-by":"crossref","unstructured":"Byrd JC, Furman RR, Coutre SE. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369(1):32-42.","DOI":"10.1056\/NEJMoa1215637"},{"key":"24642","doi-asserted-by":"crossref","unstructured":"Herman SE, Mustafa RZ, Gyamfi JA. Ibrutinib inhibits BCR and NF-\u03baB signaling and reduces tumor proliferation in tissueresident cells of patients with CLL. Blood. 2014; 123(21):3286-3295.","DOI":"10.1182\/blood-2014-02-548610"},{"key":"24643","doi-asserted-by":"crossref","unstructured":"Jayappa KD, Portell CA, Gordon VL. Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. Blood Adv. 2017; 1(14):933-946.","DOI":"10.1182\/bloodadvances.2016004176"},{"key":"24644","doi-asserted-by":"crossref","unstructured":"Fabre C, Mimura N, Bobb K. Dual inhibition of canonical and noncanonical NF-\u03baB pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res. 2012; 18(17):4669-4681.","DOI":"10.1158\/1078-0432.CCR-12-0779"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/9748\/70865","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9748\/70866","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9748\/70865","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:57:02Z","timestamp":1794045422000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/9748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,7]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2019.238584","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,7]]}}}